(AZN) AstraZeneca - Ratings and Ratios

AstraZeneca PLC is a biopharmaceutical powerhouse with a diverse portfolio of prescription medicines across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases. The companys extensive product lineup includes well-established brands such as Tagrisso, Imfinzi, Lynparza, Calquence, and Farxiga, as well as newer additions like Tezspire and Voydeya. With a global presence, AstraZeneca serves primary and specialty care physicians through distributors and local representative offices in key regions, including the UK, US, Europe, and Asia.

AstraZenecas strategic focus on innovation is evident in its partnership with Tempus to develop the largest multimodal foundation model in oncology, leveraging cutting-edge technology to drive advancements in cancer treatment. The companys commitment to research and development is reflected in its robust pipeline, which is expected to drive future growth. With a strong track record of delivering new medicines to market, AstraZeneca is poised to maintain its position as a leader in the biopharmaceutical industry.

Analyzing the , we observe that AstraZenecas stock has been trending upwards, with the short-term and long-term moving averages (SMA20 and SMA50) indicating a bullish sentiment. The stock is currently trading above its 200-day moving average (SMA200), suggesting a stable long-term trend. The Average True Range (ATR) indicates moderate volatility, with a 2.01% daily price movement. Considering the , AstraZenecas market capitalization stands at $216.78 billion, with a forward P/E ratio of 15.50, suggesting a relatively attractive valuation. The companys Return on Equity (RoE) is 19.18%, indicating strong profitability.

Based on the and , our forecast suggests that AstraZenecas stock is likely to continue its upward trend, driven by the companys robust product pipeline, strategic partnerships, and strong financial performance. We anticipate that the stock will reach $80.00 within the next 12-18 months, representing a potential upside of 10% from current levels. However, its essential to monitor the companys progress and adjust our forecast accordingly, as the biopharmaceutical industry is subject to various risks and uncertainties.